Lot #2703814

GLP-2 [60mg]

4.9 / 5

Trusted by 5,000+ researchers

60mg / vial

≥99% HPLC

Dual incretin receptor agonist

GLP-2 [60mg]

60mg / vial

Dual incretin receptor agonist

≥99% HPLC

4.9 / 5

Trusted by 5,000+ researchers

$90.00

30-day money back

2-day shipping

Signed COA on every batch

Secure checkout

Research use only · Not for human or veterinary use

COA on Every Batch

BioRegen Verified

≥99% HPLC Purity

Made in the USA

2-Day Shipping

30-Day Money Back

Researcher-grade specs. No guesswork.

Each vial ships with structural data and lot identifiers for the compound, plus a Certificate of Analysis documenting purity and identity. Ready for the bench. Synthesized via solid-phase peptide synthesis (SPPS), purified by reverse-phase HPLC, verified by mass spectrometry, and tested for sterility and endotoxin load. Every spec is documented on the signed Certificate of Analysis that ships with your vial.

Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

The molecule is built on a GIP receptor-binding scaffold with GLP-1 receptor agonist activity incorporated via sequence modification, enabling simultaneous activation of both incretin receptors. Published research has examined receptor pathway activity and metabolic signaling associated with this dual-agonist mechanism.

This product is for laboratory research use only. Not for human administration. Not intended to diagnose, treat, cure, or prevent any disease.

Documented Research Areas

Dual GIP and GLP-1 receptor binding and co-activation in vitro receptor assays

Comparative GIP/GLP-1 receptor agonism versus single-receptor incretin analogs

Glucose-dependent insulin secretion and beta-cell function in preclinical models

Body weight modulation and adipose tissue remodeling in diet-induced obesity models

Incretin receptor pathway interaction and dual-agonism synergy characterization

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Researcher-grade specs. No guesswork.

Each vial ships with structural data and lot identifiers for the compound, plus a Certificate of Analysis documenting purity and identity. Ready for the bench. Synthesized via solid-phase peptide synthesis (SPPS), purified by reverse-phase HPLC, verified by mass spectrometry, and tested for sterility and endotoxin load. Every spec is documented on the signed Certificate of Analysis that ships with your vial.

— Component 01

Tirzepatide · 60mg

Class

Dual GIP/GLP-1 receptor agonist

Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20 fatty diacid via linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser (39 aa)

CAS Number

2023788-19-2

Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight

4,813.5 g/mol

Per-component purity

≥ 98%

One compound. One research record.

Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

The molecule is built on a GIP receptor-binding scaffold with GLP-1 receptor agonist activity incorporated via sequence modification, enabling simultaneous activation of both incretin receptors. Published research has examined receptor pathway activity and metabolic signaling associated with this dual-agonist mechanism.

This product is for laboratory research use only. Not for human administration. Not intended to diagnose, treat, cure, or prevent any disease.

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Documented Research Areas

Dual GIP and GLP-1 receptor binding and co-activation in vitro receptor assays

Comparative GIP/GLP-1 receptor agonism versus single-receptor incretin analogs

Glucose-dependent insulin secretion and beta-cell function in preclinical models

Body weight modulation and adipose tissue remodeling in diet-induced obesity models

Incretin receptor pathway interaction and dual-agonism synergy characterization

A curated list of published peer-reviewed papers indexed in PubMed where BPC-157 has been studied. Provided for research-context only. Linking to the literature does not constitute endorsement of any therapeutic application.

Frias JP, et al. · N Engl J Med

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

PubMed · PubMed · 34170647

Jastreboff AM, et al. · N Engl J Med

Tirzepatide Once Weekly for the Treatment of Obesity

PubMed · PubMed · 35658024

Compound database reference for chemical and structural data:

Research You Can Trust.

At Revvd Research, quality comes first. Our peptides are produced using advanced manufacturing processes and verified through comprehensive testing protocols to deliver dependable results for research applications.

Verified Purity

0 %+

Quality Assured

0 %

USA

Produced

Every lot. Every researcher. Same proof.

Each batch ships with a third-party Certificate of Analysis from BioRegen Analytical. HPLC purity, mass-spectrometry identity, sterility, and LAL endotoxin screening. Every test, every lot.

Your lot number ships on the label and on the COA. Enter it in the verifier any time to retrieve the original lab report.

Verify Batch COA

Certificate of Analysis

CompoundTirzepatide (GLP-2)

CAS#2023788-19-2

Sequence39 aa dual GIP/GLP-1 agonist with C20 fatty diacid modification at Lys16

Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight4,813.5 g/mol

Purity (HPLC)On file

Identity (LC-MS)On file

Sterility / LALPASS

Date TestedOn file

Related compounds.

Other research peptides in the Revvd catalog cited alongside the BPC-157 + TB-500 blend in the published research literature.

GLOW [70mg]

50mg / 10mg / 10mg per vial

CAS#

49557-75-7

Formula

C₁₄H₂₄CuN₆O₄

M.W.

403.9 g/mol

Research use only · Not for human or veterinary use

$80.00

$160

BPC-157 [10mg]

10mg / vial

CAS#

137525-51-0

Formula

C₆₂H₉₈N₁₆O₂₂

M.W.

1,419.55 g/mol

Research use only · Not for human or veterinary use

$40.00

$80

BPC-157 + TB-500 [5mg/5mg]

5mg / 5mg per vial

CAS#

137525-51-0

Formula

C₆₂H₉₈N₁₆O₂₂

M.W.

1,419.55 g/mol

Research use only · Not for human or veterinary use

$47.50

$95

TESAMORELIN + IPAMORELIN [5mg/5mg]

5mg / 5mg per vial

CAS#

218949-48-5

Formula

C₂₂₁H₃₆₆N₇₂O₆₇S

M.W.

5,135.77 g/mol

Research use only · Not for human or veterinary use

$55.00

$110

Write Reviews Here

[wiserrw_product_review]

Answered straight.

The standard for research integrity.

Featured Collection – Premium purity compounds crafted with consistency, precision, and quality in mind.

Add the GLP-2 [60mg] blend to your research arsenal.

5,000+ researchers trust Revvd for batch-tested peptides. Every vial. Every COA. Every time.

30-day money back · Free shipping over $150 · 2-day shipping

Signed COA on every batch

Lot #2703814

GLP-2 [60mg]

4.9 / 5

Trusted by 5,000+ researchers

60mg / vial

≥99% HPLC

Dual incretin receptor agonist

GLP-2 [60mg]

60mg / vial

Dual incretin receptor agonist

≥99% HPLC

4.9 / 5

Trusted by 5,000+ researchers

$90.00

30-day money back

2-day shipping

Signed COA on every batch

Secure checkout

COA on Every Batch

BioRegen Verified

≥99% HPLC Purity

Made in the USA

2-Day Shipping

30-Day Money Back

Researcher-grade specs. No guesswork.

Documented Research Areas

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Researcher-grade specs. No guesswork.

One compound. One research record.

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Documented Research Areas

A curated list of published peer-reviewed papers indexed in PubMed where BPC-157 has been studied. Provided for research-context only. Linking to the literature does not constitute endorsement of any therapeutic application.

Compound database reference for chemical and structural data:

Research You Can Trust.

USA

Every lot. Every researcher. Same proof.

Each batch ships with a third-party Certificate of Analysis from BioRegen Analytical. HPLC purity, mass-spectrometry identity, sterility, and LAL endotoxin screening. Every test, every lot.

Your lot number ships on the label and on the COA. Enter it in the verifier any time to retrieve the original lab report.

Certificate of Analysis

CompoundTirzepatide (GLP-2) CAS#2023788-19-2 Sequence39 aa dual GIP/GLP-1 agonist with C20 fatty diacid modification at Lys16 Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈ Molecular Weight4,813.5 g/mol Purity (HPLC)On file Identity (LC-MS)On file Sterility / LALPASS Date TestedOn file

Related compounds.

Other research peptides in the Revvd catalog cited alongside the BPC-157 + TB-500 blend in the published research literature.

GLOW [70mg]

CAS#

Formula

M.W.

$80.00

BPC-157 [10mg]

CAS#

Formula

M.W.

$40.00

BPC-157 + TB-500 [5mg/5mg]

CAS#

Formula

M.W.

$47.50

TESAMORELIN + IPAMORELIN [5mg/5mg]

CAS#

Formula

M.W.

$55.00

Write Reviews Here

Answered straight.

What is the purity of this Tirzepatide?

Who tests it, and how do I know the results are real?

Where is it manufactured?

How is it shipped?

What's your return policy?

What's included with each vial?

How should it be stored?

Can this be used on humans or animals?

The standard for research integrity.

Add the GLP-2 [60mg] blend to your research arsenal.

5,000+ researchers trust Revvd for batch-tested peptides. Every vial. Every COA. Every time.

CompoundTirzepatide (GLP-2)

CAS#2023788-19-2

Sequence39 aa dual GIP/GLP-1 agonist with C20 fatty diacid modification at Lys16

Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight4,813.5 g/mol

Purity (HPLC)On file

Identity (LC-MS)On file

Sterility / LALPASS

Date TestedOn file